Prognostic Role of
PD-L1
cancer progression
expression
fibroblast growth factor receptor 3
microRNA
mutation
non-muscular invasive bladder carcinoma
prognosis
tumor relapse
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
23 Nov 2020
23 Nov 2020
Historique:
received:
10
10
2020
revised:
10
11
2020
accepted:
22
11
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
epublish
Résumé
bladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC). In this study we evaluated association of PD-L1 expression with other prognostic biomarkers, such as expression of miRNA-145 and miRNA-200a, twenty patients with primary luminal NMIBC were enrolled in the study. Tumor grade and risk level were determined in accordance with European Organization for Research and Treatment of Cancer (EORTC) guidelines and World Health Organization (WHO) classification. Neoplasm molecular subtype and PD-L1 expression level were assessed by immunohistochemistry. We used real-time PCR to evaluate the expression of microRNAs and high grade primary luminal NMIBC showed comparatively higher expression of PD-L1 and microRNA-145 than a low grade tumor, whereas the latter had a higher tumor grade in association with PD-L1 and
Sections du résumé
BACKGROUND
BACKGROUND
bladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC). In this study we evaluated association of PD-L1 expression with other prognostic biomarkers, such as expression of miRNA-145 and miRNA-200a,
METHODS
METHODS
twenty patients with primary luminal NMIBC were enrolled in the study. Tumor grade and risk level were determined in accordance with European Organization for Research and Treatment of Cancer (EORTC) guidelines and World Health Organization (WHO) classification. Neoplasm molecular subtype and PD-L1 expression level were assessed by immunohistochemistry. We used real-time PCR to evaluate the expression of microRNAs and
RESULTS
RESULTS
high grade primary luminal NMIBC showed comparatively higher expression of PD-L1 and microRNA-145 than a low grade tumor, whereas the latter had a higher
CONCLUSIONS
CONCLUSIONS
tumor grade in association with PD-L1 and
Identifiants
pubmed: 33238591
pii: life10110305
doi: 10.3390/life10110305
pmc: PMC7700587
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Russian academic excellence project "5-100" for Sechenov First Moscow State Medical University
ID : 1/15
Références
PLoS One. 2019 Aug 30;14(8):e0221785
pubmed: 31469885
Bladder Cancer. 2016 Jan 7;2(1):37-47
pubmed: 27376123
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Pharmacoeconomics. 2003;21(18):1315-30
pubmed: 14750899
Curr Opin Oncol. 2015 May;27(3):185-90
pubmed: 25695463
Nat Rev Clin Oncol. 2018 Apr;15(4):203-204
pubmed: 29255240
Eur Urol. 2017 Nov;72(5):801-813
pubmed: 28457661
Investig Clin Urol. 2016 Jun;57 Suppl 1:S52-9
pubmed: 27326408
Biopreserv Biobank. 2017 Apr;15(2):134-141
pubmed: 28332850
Cancers (Basel). 2019 Mar 12;11(3):
pubmed: 30871066
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Cancers (Basel). 2019 Oct 14;11(10):
pubmed: 31615011
Cancer Immunol Immunother. 2007 May;56(5):739-45
pubmed: 17195077
Urol Clin North Am. 2016 Feb;43(1):47-62
pubmed: 26614028
BMC Urol. 2018 Nov 6;18(1):97
pubmed: 30400941
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Int J Oncol. 2012 Nov;41(5):1871-8
pubmed: 22961325
Cells. 2019 May 31;8(6):
pubmed: 31159302
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Nucleic Acids Res. 2005 Nov 27;33(20):e179
pubmed: 16314309
PLoS One. 2016 Sep 21;11(9):e0161491
pubmed: 27655328
Oncol Lett. 2017 Sep;14(3):3817-3824
pubmed: 28927152
Curr Urol Rep. 2018 Oct 17;19(12):96
pubmed: 30328534
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455829
Tumour Biol. 2016 Jun;37(6):8075-82
pubmed: 26715266
Virchows Arch. 2014 Aug;465(2):207-13
pubmed: 24880661
Front Genet. 2018 Sep 28;9:422
pubmed: 30323832
World J Urol. 2019 Jan;37(1):31-40
pubmed: 30259123